# UK MHRA grants conditional approval for triheptanoin in rare metabolic disorders

> The UK Medicines and Healthcare products Regulatory Agency approved triheptanoin (Dojolvi) on 30 October as an oral liquid for adult and paediatric patients with long-chain fatty acid oxidation disorders. The regulatory decision was granted as a conditional marketing authorisation.

- Canonical URL: https://newsverum.com/en/news/uk-mhra-triheptanoin-dojolvi-approval-2026
- Publisher: Newsverum
- Section: Health
- Country: United Kingdom
- Published: 2026-10-31T22:01:30+00:00
- Updated: 2026-11-01T00:43:00Z
- Event / data period: 2026-10-30
- Other editions: [Türkçe](https://newsverum.com/tr/news/uk-mhra-triheptanoin-dojolvi-approval-2026.md), [العربية](https://newsverum.com/ar/news/uk-mhra-triheptanoin-dojolvi-approval-2026.md), [Français](https://newsverum.com/fr/news/uk-mhra-triheptanoin-dojolvi-approval-2026.md), [Español](https://newsverum.com/es/news/uk-mhra-triheptanoin-dojolvi-approval-2026.md), [Deutsch](https://newsverum.com/de/news/uk-mhra-triheptanoin-dojolvi-approval-2026.md), [Português](https://newsverum.com/pt/news/uk-mhra-triheptanoin-dojolvi-approval-2026.md)

Long-chain fatty acid oxidation disorders are rare genetic conditions that disrupt how the body converts long-chain fats into cellular energy, creating severe risks of cardiomyopathy, muscle breakdown and acute hypoglycemia. Triheptanoin, a synthetic odd-carbon medium-chain triglyceride, functions as a direct nutritional energy source to bypass defective enzymatic pathways in the Krebs cycle.

The MHRA noted that conditional authorisation requires ongoing submission of pediatric clinical efficacy and safety data to support full marketing approval. Common reported side effects include gastrointestinal symptoms such as abdominal pain, diarrhoea and nausea. The decision authorizes clinical prescribing under supervised dietary management rather than universal availability across all pharmacy channels.

## Data

### Source publication

Publication of the official conditional marketing authorisation announcement on 30 October 2026.

Methodology: The date records publication of the cited primary source. Clinical indications and regulatory constraints are stated in the article.

| date | label | description | status |
|---|---|---|---|
| 2026-10-30 | MHRA issues conditional marketing authorisation for triheptanoin | Official approval announced on 30 October 2026 for treating long-chain fatty acid oxidation disorders. | occurred |

Sources: <https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders> · Download data: [JSON](https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026/data/source-announcement?lang=en&format=json) · [CSV](https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026/data/source-announcement?lang=en&format=csv)

## Sources

- [Medicines and Healthcare products Regulatory Agency, United Kingdom](<https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders>) (Source checked: 2026-11-01; Published: 2026-10-30)

---

Cite the canonical URL above. [Editorial standards and corrections](https://newsverum.com/en/editorial)
